Gabapentin (GP) has been shown to have antihyperalgesic properties and the site of drug action is reported to be the central nervous system. The goal of the present study was to determine whether GP also has a peripheral site of action. Rats received intraplantar 20-μl injections of 6, 60 or 600 μg GP + 2% formalin, 300 or 600 μg S-(+)-3-isobutylgaba + 2% formalin, 600 μg R-(-)-3-isobutylgaba + 2% formalin or formalin alone. The two lower doses of GP significantly reduced flinching and lifting/licking behavior during phase 2; however, phase I behaviors were unaffected, 600 μg GP significantly reduced these nociceptive behaviors during both phases. 600 μg S-(+)-3- isobutylgaba also reduced formalin-induced nociceptive behaviors; however, 600 μg of the isomer R-(-)-3-isobutylgaba had no effect. The antihyperalgesic effect of GP (1) was not due to a systemic effect since animals injected with 600 μg GP in one hindpaw and 2% formalin into the contralateral hindpaw developed nociceptive behaviors which were no different than those seen in animals injected with formalin alone; (2) was not due to a local anesthetic effect since needle sticks within the drug-injected region evoked paw withdrawal behavior which was not different from pre-drug levels; (3) was blocked by 20 μl D-serine but not by L-serine. Although the mechanism of action of GP has yet to be elucidated, these results indicate that GP has a peripheral site of action and thus may offer a novel therapeutic agent for topical or local treatment of pain of peripheral origin.
|Original language||English (US)|
|Number of pages||7|
|State||Published - May 1998|
ASJC Scopus subject areas
- Clinical Neurology
- Anesthesiology and Pain Medicine